Market Intelligence, Clinical Progress, and High-Purity Reagents for Polyamine-Pathway Cancer Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ODC1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen / Enzyme | ODC1 Recombinant Protein (Wild-Type & C360A Mutant). High purity (>95%), Endotoxin <1 EU/µg, Sequence Verified. PLP cofactor binding site preserved. | View ODC1 Products |
| Gene Delivery | ODC1 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction. | View ODC1 Products |
| Benchmark Antibody | Anti-ODC1 (Assay Grade). Recombinant rabbit monoclonal for Western/ELISA/competition binding assays. | View ODC1 Products |
| Validator | ODC1 siRNA Set. For knockdown verification and polyamine depletion rescue experiments. | View ODC1 Products |
| Related Target: OAZ1 | Ornithine Decarboxylase Antizyme (OAZ1). Key negative regulator of ODC1; essential for polyamine feedback assays. | View OAZ1 Products |
| Related Target: AMD1 | Adenosylmethionine Decarboxylase 1 (AMD1). Downstream polyamine synthase; combination therapy node. | View AMD1 Products |
| Related Target: SRM | Spermidine Synthase (SRM). Polyamine pathway enzyme; bypass resistance screening. | View SRM Products |
| Related Target: SMS | Spermine Synthase (SMS). Downstream polyamine mediator. | View SMS Products |
| Related Target: AZIN1 | Antizyme Inhibitor 1 (AZIN1). Key regulatory partner controlling ODC1 degradation and polyamine feedback inhibition. | View AZIN1 Products |
Critical Assay Challenges & Technical Specifications
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular target engagement & cellular validation | ODC1 Lentivirus ORF + siRNA combo for gain/loss-of-function studies in mammalian cells |
| Drug resistance mutant screening (post-inhibitor relapse) | WT + engineered mutant ODC1 proteins (including C360A); Sequence Verified; High Purity (>95%) |
| Selectivity over other decarboxylases (PLP-dependent) | Homolog panel proteins (DDC, GAD1, AMD1, SMOX) for counter-screening; Sequence Verified |
| Enzymatic dimerization & inhibitor binding kinetics | Endotoxin controlled (<1 EU/µg); suitable for SPR/BLI and thermal shift assays |
| High background in enzymatic assays | High Purity (>95%) from E. coli / Sf9 / HEK293 expression systems; verified by mass spec |
| Isoform and ortholog cross-reactivity | Human/Mouse ortholog proteins available with Sequence Verified accuracy |
| Lack of positive controls | Benchmark inhibitor controls and anti-ODC1 antibodies included |
| Cellular knockdown verification | Validated siRNA guaranteed >80% knockdown efficiency for specificity controls |
| PLP cofactor preservation for native enzyme activity | HEK293 expressed native fold with preserved Cys360 active site; Theoretical MW 53 kDa confirmed by Mass Spec |
Key Mutations & Resistance Mechanisms
ODC1 mutations such as C360A (corresponding to UniProt VAR_085000 in BABS) are available for mechanism-of-resistance studies. These gain-of-function variants result in increased putrescine biosynthesis and reduced sensitivity to irreversible inhibitors like DFMO. Our recombinant protein portfolio includes both wild-type and engineered mutants to support drug discovery against evolving resistance.
Live ODC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
- ➤ Polyamine Metabolism Research
Global Clinical Landscape & Future Outlook
The race for ODC1 (Ornithine Decarboxylase 1) therapeutics is intensifying, with major players shifting focus from traditional mono-therapies to polyamine blockade combination strategies. First-generation irreversible inhibitors like Eflornithine (DFMO) have established polyamine depletion as a valid anti-cancer strategy, securing approvals for high-risk neuroblastoma maintenance therapy. The next wave of R&D is targeting broad-spectrum oncology applications, utilizing novel small molecules, targeted protein degraders (PROTACs), and combination regimens to overcome compensatory mechanisms in polyamine metabolism. Key areas include colorectal cancer chemoprevention, neuroblastoma maintenance, and immuno-oncology combinations where polyamine depletion reverses immunosuppressive tumor microenvironments.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Irreversible Inhibitor (DFMO/Eflornithine) | US WorldMeds, Panbela, Polaris Group, NCI | Neuroblastoma, Pancreatic Cancer, Colon Adenoma | Enzyme Activity Assay (Need PLP-bound native protein) |
| Next-Generation Small Molecule Inhibitor | Academic consortia, Emerging biotechs | Solid Tumors | Enzymatic Inhibition & Thermal Shift (Need high-purity WT and mutant ODC1) |
| PROTAC / Degrader | Early Stage Biotechs, Academic Consortia | Solid Tumors | Degradation Assay & Ternary Complex Formation (Need purified ODC1 + E3 ligase components) |
| Combination Therapy (ODC1 + polyamine pathway) | Big Pharma / Academic, University of Washington | Immuno-oncology, Prostate Cancer | Polyamine Flux Analysis (Need validated siRNA and pathway protein panel) |
| RNAi / ASO | Preclinical Labs | Hepatocellular Carcinoma | Knockdown Validation (Need Sequence Verified siRNA) |
| mRNA/DNA Vaccines (Metabolic) | Preclinical | Immuno-oncology | ODC1 Expression Validation (Need lentivirus ORF) |